Hillah

Researchers are studying how turoctocog alfa is used in everyday clinical practice for male patients with haemophilia A, a congenital bleeding disorder. This observational retrospective study aims to describe treatment patterns and provide baseline information for managing haemophilia A without changing participants' clinical care. The study focuses on patients who have previously received factor VIII (FVIII) replacement therapy and are now switching to turoctocog alfa. Turoctocog alfa, administered intravenously, is the drug being observed in this study. Data is collected from patients who switch from their previous FVIII therapy to turoctocog alfa. The study does not involve new treatments or interventions but relies on existing medical records uploaded to a special electronic database. Participants' baseline history is recorded at the time they switch to turoctocog alfa, and outcomes are tracked according to their regular clinic visits. The main outcome measured is the annual bleeding rate (ABR) over 12 months following the switch. This helps researchers understand how different turoctocog alfa treatment regimens affect bleeding events in these patients.